AlphaYouPB
Schedule 13G filing
Paradigm Biocapital Advisors LP disclosed a 5.1% stake in Spyre Therapeutics, Inc. (SYRE)
Paradigm Biocapital Advisors LP reported owning 5.1% of Spyre Therapeutics, Inc. (SYRE) (4,457,450 shares) in a Schedule 13G filed Oct 1, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 1, 2026
- Source
- Schedule 13G
More SYRE insider and Congress trades
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.